Suprachiasmatic nucleus and melatonin: Reciprocal interactions and clinical correlations

Neurology

Volumn 71, Issue 8, 2008, Pages 594-598

  Benarroch, Eduardo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ARGIPRESSIN; CALCIUM; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MELATONIN; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE;

AGING; ALZHEIMER DISEASE; ARTICLE; CALCIUM CELL LEVEL; CIRCADIAN RHYTHM; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; HUMAN; HYPOTHALAMUS; LIGHT DARK CYCLE; MESENCEPHALON; NEUROPROTECTION; PINEAL BODY; PRIORITY JOURNAL; PROTEIN BINDING; RETINA; SEROTONINERGIC NERVE CELL; SIGNAL TRANSDUCTION; SLEEP DISORDER; SUPRACHIASMATIC NUCLEUS; ANIMAL; METABOLISM; PHYSIOLOGY; REVIEW; SECRETION; SYNDROME;

AGING; ALZHEIMER DISEASE; ANIMALS; CIRCADIAN RHYTHM; HUMANS; MELATONIN; PINEAL GLAND; SLEEP DISORDERS; SUPRACHIASMATIC NUCLEUS; SYNDROME;

EID: 54749103977     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000324283.57261.37     Document Type: Article

References (27)

1. Zee PC, Manthena P. The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med Rev 2007;11:59-70.
2. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet 2006;15:R271-277.
3. Challet E. Minireview: entrainment of the suprachiasmatic clockwork in diurnal and nocturnal mammals. Endocrinology 2007;148:5648-5655.
4. Berson DM. Phototransduction in ganglion-cell photore-ceptors. Pflugers Arch 2007;454:849-855.
5. Foster R, Bellingham J. Opsins and melanopsins. Curr Biol 2002;12:R543-544.
6. Hannibal J, Fahrenkrug J. Neuronal input pathways to the brain's biological clock and their functional significance. Adv Anat Embryol Cell Biol 2006;182:1-71.
7. Moore RY, Speh JC. Serotonin innervation of the primate suprachiasmatic nucleus. Brain Res 2004;1010:169-173.
8. Saper CB, Lu J, Chou TC, Gooley J. The hypothalamic integrator for circadian rhythms. Trends Neurosci 2005;28:152-157.
9. Moore RY, Speh JC, Leak RK. Suprachiasmatic nucleus organization. Cell Tissue Res 2002;309:89-98.
10. Aton SJ, Colwell CS, Harmar AJ, Waschek J, Herzog ED. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci 2005;8:476-483.
11. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: nature's most versatile biological signal? Febs J 2006;273:2813-2838.
12. Maronde E, Stehle JH. The mammalian pineal gland: known facts, unknown facets. Trends Endocrinol Metab 2007;18:142-149.
13. Lack LC, Wright HR. Chronobiology of sleep in humans. Cell Mol Life Sci 2007;64:1205-1215.
14. Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 2006;60:97-108.
15. Ayoub MA, Levoye A, Delagrange P, Jockers R. Preferential formation of MT1/MT2 melatonin receptor het-erodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol Pharmacol 2004; 66:312-321.
16. Cajochen C, Munch M, Knoblauch V, Blatter K, Wirz-Justice A. Age-related changes in the circadian and homeo-static regulation of human sleep. Chronobiol Int 2006;23: 461-474.
17. Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med 2007;8:623-636.
18. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003;26:893-901.
19. Serfaty M, Kennell-Webb S, Warner J, Blizard R, Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geri-atr Psychiatry 2002;17:1120-1127.
20. Reiter RJ, Tan DX, Terron MP, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007;54:1-9.
21. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol 2007;3:221-228.
22. Lack LC, Wright HR. Treating chronobiological components of chronic insomnia. Sleep Med 2007;8:637-644.
23. Morgenthaler TI, Lee-Chiong T, Alessi C, et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep 2007;30:1445-1459.
24. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281-284.
25. Ghosh A, Hellewell JS. A review of the efficacy and tolera-bility of agomelatine in the treatment of major depression. Exp Opin Invest Drugs 2007;16:1999-2004.
26. Gropman AL, Elsea S, Duncan WC Jr, Smith AC. New developments in Smith-Magenis syndrome (del 17p11.2). Curr Opin Neurol 2007;20:125-134.
27. De Leersnyder H. Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment. Trends Endocrinol Metab 2006;17:291-298.